PDE9A

Across TCGA pan-cancer cohorts, PDE9A Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PDE9A data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PDE9A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDE9A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, LIHC, and LUSC are the cancer types where PDE9A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LIHC	OS	Median	All	0.452	0.778	.007	18	view →
LUSC	OS	Median	II,III,IV	0.210	0.735	.002	12	view →
UCEC	OS	Median	All	1.000	0.660	.022	12	view →
PRAD	DFS	Median	All	0.599	0.935	.035	6	view →
STAD	OS	Median	II,III,IV	0.253	0.662	.030	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.023	3	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →
LUAD	DFS	Median	All	0.559	0.814	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PDE9A–THYM (OS)

Open the THYM breakdown →